UK

Verino® Pro SARS-CoV-2 Ag Rapid Test

COVID-19 Overview

Coronavirus disease 2019 (COVID‐19) is of zoonotic origin and caused by the novel beta coronavirus, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.

 

Product Information

Verino® Pro SARS-CoV-2 Ag Rapid Test is is an in vitro immunochromatographic assay for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human nasal swab, oropharyngeal swab or nasopharyngeal swab specimen.
It is intended to aid in the rapid diagnosis of SARS-CoV-2 infections.

 

Ordering Information

Catalog Number Description Format Size
56281 Verino PRO SARS-CoV-2 Ag rapid test Cassette 25 tests

Benefits

• Rapid 15 minute testing for SARS-CoV-2 antigen
• Facilitates quick patient treatment decisions
• Simple, time saving procedure
• All necessary reagents provided and no equipment needed
• High sensitivity and specificity

Specification

Time to result 15 minutes
Storage 2-30°C
Shelf life 24 months
Specymen type Nasal swab, Oropharyngeal swab, Nasopharyngeal swab

Contents

• 25 Test cassettes
• 25 Sterile swabs
• 25 Extraction tubes and dropper tips
• 1 Package insert

Performance Characteristics

Verino® Pro SARS-CoV-2 Ag Rapid Test has been evaluated with specimens obtained from patiets. The performance of the tests was compared to a commercialized molecular assay.

Clinical Sensitivity: 97.42%
Clinical Specificity: >99.99%
Clinical Accuracy: 99.32%

Our Values

10 core values have influenced the progress of our group.

READ MORE »